Evidence map›Paper›PMID 41455028›Full record

ArticleEJNMMI research2025

Establishment and validation of a clinical threshold criteria for choosing PET imaging tracers for indolent non-Hodgkin's lymphoma.

Xuebing Yu, Hailong Tang, Hengyi Ou, Zhiyong Quan, Guiyu Li, Guangxun Gao, Jing Wang, Fei Kang

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06834412 ([68Ga]Pentixafor PET/CT for Staging of Hematological Malignancies), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06834412 narecruitingnot on this map

[68Ga]Pentixafor PET/CT for Staging of Hematological Malignancies: Comparison to [18F]FDG PET/CT

TypeinterventionalSponsorXijing HospitalRan2021 to 2025Enrolled120ConditionsHematological MalignanciesArms68Ga-Pentixafor and 18F-FDG PET/CT Scan
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xuebing Yu *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Hailong Tang *Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Hengyi Ou *Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Zhiyong QuanDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Guiyu LiDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China.
Guangxun GaoDepartment of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. gaoguangxun@fmmu.edu.cn.
Jing WangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. 13909245902@163.com.
Fei KangDepartment of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, Shaanxi, China. fmmukangf@fmmu.edu.cn.ORCID http://orcid.org/0000-0003-0267-7819

Funding

National Natural Science Foundation of China 82470203National Natural Science Foundation of China 92259304Shaanxi Province Health and Wellness Innovation Team 2023TD-03Shaanxi Province Key Industry Innovation Chain (Group) 2024SF-ZDCYL-02-06the Innovation Project of Xijing Hospital XJZT25CX50Xijing Hospital Medical Personnel Training Promotion Project 2024XJSM04Xijing Hospital Medical Personnel Training Promotion Project 2024XJSY35
6 · The paper itself

Abstract

background[

resultsIn the retrospective real-world cohort of NHL, Ki67 was identified as an independent factor that influenced [

conclusionA Ki67 of 35% was shown to be a promising threshold criterion for choosing between [

trial registrationA Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing it With 18 F-FDG PET/CT Imaging, NCT06834412. Registered 13 February 2025 - Retrospectively registered, https://register. CLINICALTRIALS: gov/prs/beta/studies/S000FBBP00000062 .

Indexed as

[68Ga]PentixaforCXCR4LymphomaPET/CT

Identifiers

PMID41455028
PMCPMC12858696

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.